Brad Bolzon is a Managing Director who brings more than 13 years of global pharmaceutical industry experience to Versant’s biotech investment team. He specializes in early-stage biotech investing with a particular emphasis on new company start-ups.
Prior to joining Versant, Brad served as Executive Vice President, Global Head of Business Development, Licensing & Alliances with F. Hoffmann-La Roche. Under his leadership, Roche established alliances with more than 75 biotech companies worldwide and significantly strengthened its product pipeline. Previously, Brad held executive roles at Eli Lilly in drug discovery, clinical research, regulatory affairs, and business development. Brad Bolzon earned his Ph.D. from University of Toronto and completed post-doctoral research at the Ottowa Heart Institute.